Inicio
Resultado de la búsqueda
15 búsqueda de la palabra clave 'cancer'
Clasificado(s) por (Año de edición descendente) Refinar búsqueda Genera el flujo rss de la búsqueda
Enlace permanente de la investigación
Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective / Kenny Mauricio Gálvez Cárdenas
Título : Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective Tipo de documento : documento electrónico Autores : Kenny Mauricio Gálvez Cárdenas, Fecha de publicación : 2022 Títulos uniformes : Clinical and Applied Thrombosis/Hemostasis Idioma : Inglés (eng) Palabras clave : anticoagulation cancer venous thromboembolism Resumen : Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable. Mención de responsabilidad : Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen Referencia : Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988. DOI (Digital Object Identifier) : 10.1177/10760296221082988 PMID : 35261295 Derechos de uso : CC BY-NC En línea : https://journals.sagepub.com/doi/10.1177/10760296221082988 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6013 Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: a Latin American perspective [documento electrónico] / Kenny Mauricio Gálvez Cárdenas, . - 2022.
Obra : Clinical and Applied Thrombosis/Hemostasis
Idioma : Inglés (eng)
Palabras clave : anticoagulation cancer venous thromboembolism Resumen : Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients with cancer. On the basis of results from randomized controlled trials, direct oral anticoagulants (DOACs) are now recommended for the treatment of cancer-associated VTE. The decision to use a DOAC requires consideration of bleeding risk, particularly in patients with gastrointestinal (GI) malignancies, the cost-benefit and convenience of oral therapy, and patient preference. While efficacy with apixaban, edoxaban, and rivaroxaban versus dalteparin has been consistent in the treatment of cancer-associated VTE, heterogeneity is evident with respect to major GI bleeding, with an increased risk with edoxaban and rivaroxaban but not apixaban. Although cost and accessibility vary in different countries of Latin America, DOACs should be considered for the long-term treatment of cancer-associated VTE in all patients who are likely to benefit. Apixaban may be the preferred DOAC in patients with GI malignancies and LMWH may be preferred for patients with upper or unresected lower GI tumors. Vitamin K antagonists should only be used for anticoagulation when DOACs and low molecular weight heparin are inaccessible or unsuitable. Mención de responsabilidad : Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales, Alexander T Cohen Referencia : Clin Appl Thromb Hemost. Jan-Dec 2022;28:10760296221082988. DOI (Digital Object Identifier) : 10.1177/10760296221082988 PMID : 35261295 Derechos de uso : CC BY-NC En línea : https://journals.sagepub.com/doi/10.1177/10760296221082988 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6013 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001850 AC-2022-019 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-019Adobe Acrobat PDF Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura / Jhon Lidemberto Cárdenas Cárdenas
Título : Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura Otros títulos : Continuous subcutaneous infusion of morphine in a patient with advanced tumor dyspnea. Case report and literature review Tipo de documento : documento electrónico Autores : Jhon Lidemberto Cárdenas Cárdenas, Fecha de publicación : 2022 Títulos uniformes : Revista Colombiana de Cancerología Idioma : Español (spa) Palabras clave : disnea cáncer opioides infusion subcutánea Resumen : Se plantea un caso clínico en un paciente con disnea tumoral asociada a una enfermedad oncológica avanzada y en progresión que requiere manejo sintomático y que precisó de diferentes estrategias farmacológicas, alcanzando mayor beneficio con la administración de opioides a través de infusión subcutánea continua. Se hace al final una revisión en el manejo de la disnea tumoral con énfasis en la utilidad de este tipo de estrategia comparándola con otras disponibles. Mención de responsabilidad : John Lidemberto Cardenas Cardenas DOI (Digital Object Identifier) : 10.35509/01239015.794 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacancercol.org/index.php/cancer/article/view/794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6036 Infusión subcutánea continua de morfina en paciente con disnea tumoral avanzada. Reporte de caso y revisión de la literatura = Continuous subcutaneous infusion of morphine in a patient with advanced tumor dyspnea. Case report and literature review [documento electrónico] / Jhon Lidemberto Cárdenas Cárdenas, . - 2022.
Obra : Revista Colombiana de Cancerología
Idioma : Español (spa)
Palabras clave : disnea cáncer opioides infusion subcutánea Resumen : Se plantea un caso clínico en un paciente con disnea tumoral asociada a una enfermedad oncológica avanzada y en progresión que requiere manejo sintomático y que precisó de diferentes estrategias farmacológicas, alcanzando mayor beneficio con la administración de opioides a través de infusión subcutánea continua. Se hace al final una revisión en el manejo de la disnea tumoral con énfasis en la utilidad de este tipo de estrategia comparándola con otras disponibles. Mención de responsabilidad : John Lidemberto Cardenas Cardenas DOI (Digital Object Identifier) : 10.35509/01239015.794 Derechos de uso : CC BY-NC-ND En línea : https://www.revistacancercol.org/index.php/cancer/article/view/794 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=6036 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001878 AC-2022-043 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2022-043Adobe Acrobat PDF
Título : End-of-life transfusions in patients with an oncological diagnosis Otros títulos : Transfusiones al final de la vida en pacientes con diagnóstico oncológico Tipo de documento : documento electrónico Autores : Juan Felipe Vargas Silva, Fecha de publicación : 2021 Títulos uniformes : Revista de la Sociedad Española del Dolor Idioma : Inglés (eng) Palabras clave : Blood transfusion hospice care quality of life cancer pain Resumen : Introduction: Cancer patients in terminal stages present symptoms related to anemia, other cytopenias, and coagulopathies that deteriorate the quality of life. These symptoms can be multicausal and do not improve in most cases. Objective: Describe the use of blood transfusions in the six months before death as an alternative palliative treatment in patients with an oncological diagnosis in the city of Medellin during the period 2013-2018. Methods: Retrospective cohort, in patients with a cancer diagnosis who received transfusions in the last six months of life, a non-probabilistic sampling of consecutive cases was executed. The analysis was carried out in SPSS, estimating absolute and relative frequencies and median with interquartile ranges. Results: Out of 3,254 medical records of cancer patients, 151 were included. The time to oncological diagnosis had a median of 2 years (IQR 1 and 3). The symptoms observed in patients before and after the first transfusion were pain, present in 32.1 % (46) and 16.9 % (25) respectively, besides drowsiness was distinguished in 25 % (36) before transfusion and 14.3 % (21) after. Finally, the clinical outcomes before and after the last transfusion prior to death, were a decrease in pain, asthenia/adynamia, drowsiness, among others. Conclusions: The findings of this research allow us to appreciate the current panorama in the institutions in which palliative care medical services are being provided and consider when to offer the blood products to a patient at the end of life as a therapeutic measure in the context of a human being cared by physicians. Mención de responsabilidad : AP Brome Uribe, LM Martínez Sánchez, L Herrera-Almanza, M Fonseca-Guzmán, C Durango-Sánchez, V Vasquez-Estrada, L Duque-Echeverri, A Morales-Montoya, ME Saavedra-Valencia, JF Vargas-Silva, SM Molina-Giraldo DOI (Digital Object Identifier) : 10.20986/resed.2022.3956/2021 Derechos de uso : CC BY-NC-ND En línea : https://www.resed.es/transfusiones-al-final-de-la-vida-en-pacientes-con-diagnost [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5991 End-of-life transfusions in patients with an oncological diagnosis = Transfusiones al final de la vida en pacientes con diagnóstico oncológico [documento electrónico] / Juan Felipe Vargas Silva, . - 2021.
Obra : Revista de la Sociedad Española del Dolor
Idioma : Inglés (eng)
Palabras clave : Blood transfusion hospice care quality of life cancer pain Resumen : Introduction: Cancer patients in terminal stages present symptoms related to anemia, other cytopenias, and coagulopathies that deteriorate the quality of life. These symptoms can be multicausal and do not improve in most cases. Objective: Describe the use of blood transfusions in the six months before death as an alternative palliative treatment in patients with an oncological diagnosis in the city of Medellin during the period 2013-2018. Methods: Retrospective cohort, in patients with a cancer diagnosis who received transfusions in the last six months of life, a non-probabilistic sampling of consecutive cases was executed. The analysis was carried out in SPSS, estimating absolute and relative frequencies and median with interquartile ranges. Results: Out of 3,254 medical records of cancer patients, 151 were included. The time to oncological diagnosis had a median of 2 years (IQR 1 and 3). The symptoms observed in patients before and after the first transfusion were pain, present in 32.1 % (46) and 16.9 % (25) respectively, besides drowsiness was distinguished in 25 % (36) before transfusion and 14.3 % (21) after. Finally, the clinical outcomes before and after the last transfusion prior to death, were a decrease in pain, asthenia/adynamia, drowsiness, among others. Conclusions: The findings of this research allow us to appreciate the current panorama in the institutions in which palliative care medical services are being provided and consider when to offer the blood products to a patient at the end of life as a therapeutic measure in the context of a human being cared by physicians. Mención de responsabilidad : AP Brome Uribe, LM Martínez Sánchez, L Herrera-Almanza, M Fonseca-Guzmán, C Durango-Sánchez, V Vasquez-Estrada, L Duque-Echeverri, A Morales-Montoya, ME Saavedra-Valencia, JF Vargas-Silva, SM Molina-Giraldo DOI (Digital Object Identifier) : 10.20986/resed.2022.3956/2021 Derechos de uso : CC BY-NC-ND En línea : https://www.resed.es/transfusiones-al-final-de-la-vida-en-pacientes-con-diagnost [...] Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5991 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001961 AC-2021-156 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
AC-2021-156Adobe Acrobat PDF Impact of COVID-19 infection on patients with cancer: experience in a Latin American country: the ACHOCC-19 study / Alicia Quiroga Echeverri
Título : Impact of COVID-19 infection on patients with cancer: experience in a Latin American country: the ACHOCC-19 study Tipo de documento : documento electrónico Autores : Alicia Quiroga Echeverri, Fecha de publicación : 2021 Títulos uniformes : The Oncologist Idioma : Inglés (eng) Palabras clave : Cancer Covid-19 Latin America mortality survival Resumen : Introduction: The ACHOCC-19 study was performed to characterize COVID-19 infection in our oncological population. Methodology: Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression. Results: 742 patients were included. 72% > 51 years. The most prevalent neoplasms were breast (132 [17,77%]), colorectal (92 12,34%), and prostate (81 [10,9%]). 220 (29,6%) patients were asymptomatic and 96 (26,3%) died. In the bivariate descriptive analysis, higher mortality in patients > 70 years, lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute phase reactants. In the logistic regression analysis, higher mortality with ECOG 3 OR 28,67 (8,2-99,6), ECOG 4 OR 20,89 (3,36-129,7), two complications from COVID-19 OR 5,3 (1,50-18,1), and cancer in progression OR 02,08 (1,01-4,27). In the Cox regression analysis, the statistically significant HRs were metastatic disease HR 1,58 (1,16 - 2,16), cancer in progression HR 1,08 (1,24 - 2,61) vs partial response HR 0,31 (0,11 - 0,88), use of steroids HR 1,44 (1,01 - 2,06) and antibiotics HR 2,11 (1,47 - 2,95). Interpretations: In our study, cancer patients have higher mortality due to COVID-19 infection if they have active cancer, metastatic or progressive cancer, ECOG status >2 and low socioeconomic status. Implications for practice: Our findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired ECOG to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment. Mención de responsabilidad : Aylen Vanessa Ospina, Ricardo Bruges, William Mantilla, Iván Triana, Pedro Ramos, Sandra Aruachan, Alicia Quiroga, Isabel Munevar, Juan Ortiz, Néstor Llinás, Paola Pinilla, Henry Vargas, Henry Idrobo, Andrea Russi, Ray Manneh Kopp, Giovanna Rivas, Héctor González, Daniel Santa, Jesús Insuasty, Laura Bernal, Jorge Otero, Carlos Vargas, Javier Pacheco, Carmen Alcalá, Paola Jiménez, Milton Lombana, Fernando Contreras, Javier Segovia, Luis Pino, José Lobatón, Manuel González, Javier Cuello, Juliana Bogoya, Angela Barrero, Gilberto de Lima Lopes Jr Referencia : Oncologist. 2021 Oct;26(10):e1761-e1773. DOI (Digital Object Identifier) : 10.1002/onco.13861 PMID : 34132449 En línea : https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13861 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5791 Impact of COVID-19 infection on patients with cancer: experience in a Latin American country: the ACHOCC-19 study [documento electrónico] / Alicia Quiroga Echeverri, . - 2021.
Obra : The Oncologist
Idioma : Inglés (eng)
Palabras clave : Cancer Covid-19 Latin America mortality survival Resumen : Introduction: The ACHOCC-19 study was performed to characterize COVID-19 infection in our oncological population. Methodology: Analytical cohort study of patients with cancer and COVID-19 infection in Colombia. From April 1 to October 31, 2020. Demographic and clinical variables related to cancer and COVID-19 infection were collected. The primary outcome was 30-day mortality from all causes. The association between the outcome and the prognostic variables was analyzed using logistic regression models and survival analysis with Cox regression. Results: 742 patients were included. 72% > 51 years. The most prevalent neoplasms were breast (132 [17,77%]), colorectal (92 12,34%), and prostate (81 [10,9%]). 220 (29,6%) patients were asymptomatic and 96 (26,3%) died. In the bivariate descriptive analysis, higher mortality in patients > 70 years, lung cancer, ≥2 comorbidities, former smokers, receiving antibiotics, corticosteroids, and anticoagulants, residents of rural areas, low socioeconomic status, and increased acute phase reactants. In the logistic regression analysis, higher mortality with ECOG 3 OR 28,67 (8,2-99,6), ECOG 4 OR 20,89 (3,36-129,7), two complications from COVID-19 OR 5,3 (1,50-18,1), and cancer in progression OR 02,08 (1,01-4,27). In the Cox regression analysis, the statistically significant HRs were metastatic disease HR 1,58 (1,16 - 2,16), cancer in progression HR 1,08 (1,24 - 2,61) vs partial response HR 0,31 (0,11 - 0,88), use of steroids HR 1,44 (1,01 - 2,06) and antibiotics HR 2,11 (1,47 - 2,95). Interpretations: In our study, cancer patients have higher mortality due to COVID-19 infection if they have active cancer, metastatic or progressive cancer, ECOG status >2 and low socioeconomic status. Implications for practice: Our findings raise the need to carefully evaluate patients with metastatic cancer, in progression, and with impaired ECOG to define the relevance of cancer treatment during the pandemic, consider the risk/benefit of the interventions, and establish clear and complete communication with the patients and their families about the risk of complications. There is also the importance of offering additional support to patients with low income and residence in rural areas so that they can have more support during cancer treatment. Mención de responsabilidad : Aylen Vanessa Ospina, Ricardo Bruges, William Mantilla, Iván Triana, Pedro Ramos, Sandra Aruachan, Alicia Quiroga, Isabel Munevar, Juan Ortiz, Néstor Llinás, Paola Pinilla, Henry Vargas, Henry Idrobo, Andrea Russi, Ray Manneh Kopp, Giovanna Rivas, Héctor González, Daniel Santa, Jesús Insuasty, Laura Bernal, Jorge Otero, Carlos Vargas, Javier Pacheco, Carmen Alcalá, Paola Jiménez, Milton Lombana, Fernando Contreras, Javier Segovia, Luis Pino, José Lobatón, Manuel González, Javier Cuello, Juliana Bogoya, Angela Barrero, Gilberto de Lima Lopes Jr Referencia : Oncologist. 2021 Oct;26(10):e1761-e1773. DOI (Digital Object Identifier) : 10.1002/onco.13861 PMID : 34132449 En línea : https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13861 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5791 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001722 AC-2021-041 Archivo digital Producción Científica Artículos científicos Disponible Carcinoma papilar de tiroides variante de células en tachuela: Reporte de caso y revisión de la literatura / Alejandro Vélez Hoyos
Título : Carcinoma papilar de tiroides variante de células en tachuela: Reporte de caso y revisión de la literatura Tipo de documento : documento electrónico Autores : Alejandro Vélez Hoyos, Fecha de publicación : 2020 Títulos uniformes : Revista Colombiana de Patología Idioma : Español (spa) Palabras clave : Tiroides Cáncer variante células en Tachuela Resumen : El Carcinoma papilar de tiroides (CPT) es la más común de las neoplasias de la glándula, correspondiendo al 85-90% de estas, y se suele asociar a buen pronóstico, sin embargo, comprende más de 13 variantes histopatológicas, algunas de las cuales son más agresivas como la micropapilar o de células en tachuela. Ésta última se asocia a una mayor incidencia de metástasis a ganglios (68% a 75%), metástasis a distancia, angioinvasión (41.7% a 71.4%) y una mayor tasa de mortalidad (hasta de 57%). A continuación presentamos dos casos de carcinoma papilar con variante de células en tachuela, los cuales describen de forma típica la evolución e histopatología de la enfermedad. Mención de responsabilidad : Monsalve, Claudia M.D., Simón Duque, Carlos M.D., Gil, Sara M M.D., Gómez, Marcela M.D., Romero, Alfredo E. M.D., Vélez Hoyos, Alejandro M.D. Vélez, Isabela En línea : https://drive.google.com/file/d/1Ri_OXGtu2uRtYBTz9YhNnqko_qes0f4v/view Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5157 Carcinoma papilar de tiroides variante de células en tachuela: Reporte de caso y revisión de la literatura [documento electrónico] / Alejandro Vélez Hoyos, . - 2020.
Obra : Revista Colombiana de Patología
Idioma : Español (spa)
Palabras clave : Tiroides Cáncer variante células en Tachuela Resumen : El Carcinoma papilar de tiroides (CPT) es la más común de las neoplasias de la glándula, correspondiendo al 85-90% de estas, y se suele asociar a buen pronóstico, sin embargo, comprende más de 13 variantes histopatológicas, algunas de las cuales son más agresivas como la micropapilar o de células en tachuela. Ésta última se asocia a una mayor incidencia de metástasis a ganglios (68% a 75%), metástasis a distancia, angioinvasión (41.7% a 71.4%) y una mayor tasa de mortalidad (hasta de 57%). A continuación presentamos dos casos de carcinoma papilar con variante de células en tachuela, los cuales describen de forma típica la evolución e histopatología de la enfermedad. Mención de responsabilidad : Monsalve, Claudia M.D., Simón Duque, Carlos M.D., Gil, Sara M M.D., Gómez, Marcela M.D., Romero, Alfredo E. M.D., Vélez Hoyos, Alejandro M.D. Vélez, Isabela En línea : https://drive.google.com/file/d/1Ri_OXGtu2uRtYBTz9YhNnqko_qes0f4v/view Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5157 Reserva
Reservar este documentoEjemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001589 AC-2020-095 Archivo digital Producción Científica Artículos científicos Disponible Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn’s and Colitis Organisation (PANCCO) (Segunda parte) / Fabián Juliao BañosPermalinkPermalinkFactors associated with recurrence and survival in liver transplant patients with HCC - a single center retrospective study / Sergio Iván Hoyos Duque ; Carlos Ernesto Guzmán Luna ; Álvaro Mena Hurtado ; Juan Carlos Restrepo Gutiérrez ; Gonzalo Correa Arango ; Juan Camilo Pérez CadavidPermalinkPermalinkPermalink